The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a https://anyabxur231551.eqnextwiki.com/5439577/retatrutide_vs_tirzepatide_a_comparative_analysis